Gastrinoma Terminated Phase 2 Trials for Everolimus (DB01590)

Also known as: Gastrinomas

IndicationStatusPhase
DBCOND0000822 (Gastrinoma)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02031536Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With SurgeryTreatment
NCT02273752Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney CancerTreatment